Gilead Sciences | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Agios Pharmaceuticals USD 52.37M 28.79M 2025-03
ALKERMES USD 443.73M 21.47M 2025-03
Alnylam Pharmaceuticals USD 1.08B 110.65M 2025-03
Amgen USD 23.01B 91M 2025-03
Biogen USD 5.3B 231.4M 2025-03
BioMarin Pharmaceutical USD 628.21M 21.22M 2025-03
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Eli Lilly USD 30.07B 1.69B 2025-03
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 20.83B 866M 2025-03
Glaxosmithkline GBP 21.7B 238M 2024-12
Incyte USD 1.89B 244.96M 2025-03
J&J USD 56.9B 6.58B 2025-03
Merck USD 25.17B 3.25B 2025-03
Moderna USD 1.6B 602M 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 36.45B 6.54B 2025-03
PTC Therapeutics USD 595.39M 14.41M 2025-03
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Sanofi 32.22B 3.06B 2025-03
Sarepta Therapeutics USD 605.59M 126.1M 2025-03
United Therapeutics USD 721.5M 16.6M 2025-03
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Gilead Sciences Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Jul 2025.